📰 Key Takeaways

Huawei announced on Monday that rival Qualcomm will pay to use its patents for the first time, as the two companies reached a cross-licensing agreement covering 5G and AI technology. The deal marks a major breakthrough for the Chinese company’s IP portfolio, though it still needs to clear review by US regulators before taking effect.

Qualcomm first started paying to license some of Huawei’s patented technology back in 2001, and this new cross-licensing deal, once approved, would make Qualcomm a “net payer” in this patent relationship for the first time — meaning Qualcomm would pay Huawei more in licensing fees than Huawei pays Qualcomm. This shift reflects Huawei’s steady accumulation of patents in 5G and AI-related technology over recent years, and the growing leverage that comes with it. Since the deal involves Qualcomm, a US company, it’s subject to review by US regulators as required, and whether it clears that process remains to be seen. The original report doesn’t give specifics on licensing amounts, patent counts, or review timelines — check the source link for more details.

💬 JudyAI Lab Take

This news about Qualcomm becoming a paying party for the first time signals a shift in leverage around Huawei’s 5G and AI patent portfolio — worth paying attention to as a sign of where technical dominance is moving.

This cross-licensing reversal points to a broader industry pattern: patent leverage doesn’t just come from being first to market — it’s a long-term asset built through sustained investment. Qualcomm started paying Huawei for tech licenses back in 2001, and now the roles have flipped, showing that technological leadership takes time to build and isn’t permanent. For AI builders, this is a reminder that when you’re evaluating a tech stack or a partner, don’t just look at current market share and buzz — pay attention to how the underlying tech and IP landscape is shifting over time. Those shifts often signal industry reshuffling before it shows up in surface-level product moves. That said, the deal is still pending US regulatory review, and the original report doesn’t disclose specific licensing amounts or patent scope.

We’d recommend readers track how this review plays out, and keep an eye on how this kind of cross-border patent deal could affect the tech supply chains they rely on.

📅 Source Info

🔗 Further Reading